Forte Biosciences, Inc. Common Stock
Here’s whether Forte Biosciences, Inc. Common Stock (FBRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+31.69% over 10 days); strong 1-year return of +592.4%; 3-month momentum positive (+256.3%). Concerns: RSI 70 — overbought, elevated pullback risk. Currently 0.4% off its 52-week high. Score: +5/7.
FBRX is in a confirmed uptrend, trading above both its 50-day ($49.18) and 200-day ($31.22) moving averages. With an RSI of 70.1, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +592.4% compares to +20.5% for SPY (beat the market by 571.9%).